SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 08, 2023 16:05 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 05, 2023 00:32 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
December 04, 2023 16:13 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 29, 2023 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
November 27, 2023 18:04 ET
|
SpringWorks Therapeutics, Inc.
– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain,...
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
November 16, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review – – Mirdametinib treatment resulted in deep and durable...
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 02, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 – – On track to report topline data from the Phase 2b ReNeu trial of mirdametinib in...
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
November 01, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
- Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools - STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE)...
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
September 11, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...